- Home
- SDST vs NRSN Comparison
SDST vs NRSN Comparison
Compare SDST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDST
- NRSN
- Stock Information
- Founded
- SDST 2022
- NRSN 2017
- Country
- SDST United States
- NRSN Israel
- Employees
- SDST N/A
- NRSN N/A
- Industry
- SDST Blank Checks
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SDST Finance
- NRSN Health Care
- Exchange
- SDST Nasdaq
- NRSN Nasdaq
- Market Cap
- SDST 34.3M
- NRSN 31.1M
- IPO Year
- SDST N/A
- NRSN 2021
- Fundamental
- Price
- SDST $4.03
- NRSN $1.15
- Analyst Decision
- SDST Buy
- NRSN Buy
- Analyst Count
- SDST 2
- NRSN 2
- Target Price
- SDST $17.00
- NRSN $14.00
- AVG Volume (30 Days)
- SDST 352.5K
- NRSN 1.3M
- Earning Date
- SDST 11-12-2025
- NRSN 09-17-2025
- Dividend Yield
- SDST N/A
- NRSN N/A
- EPS Growth
- SDST N/A
- NRSN N/A
- EPS
- SDST N/A
- NRSN N/A
- Revenue
- SDST N/A
- NRSN N/A
- Revenue This Year
- SDST N/A
- NRSN N/A
- Revenue Next Year
- SDST N/A
- NRSN N/A
- P/E Ratio
- SDST N/A
- NRSN N/A
- Revenue Growth
- SDST N/A
- NRSN N/A
- 52 Week Low
- SDST $1.43
- NRSN $0.80
- 52 Week High
- SDST $101.20
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- SDST 81.50
- NRSN 40.37
- Support Level
- SDST $2.98
- NRSN $1.12
- Resistance Level
- SDST $3.33
- NRSN $1.26
- Average True Range (ATR)
- SDST 0.31
- NRSN 0.07
- MACD
- SDST 0.02
- NRSN 0.01
- Stochastic Oscillator
- SDST 85.80
- NRSN 16.73
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.